M9241

DRUG2 trials

Conditions

Advanced Solid TumorsHistologically or Cytologically Confirmed Pancreatic CancerMetastatic Pancreatic CancerPancreatic CancerPancreatic NeoplasmsUnresectable or Borderline Resectable Pancreatic Cancer

Phase 1

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

TerminatedNCT02994953

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumors

Start: 2017-01-31End: 2020-10-08Updated: 2024-09-20

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

TerminatedNCT04327986

National Cancer Institute (NCI)Histologically or Cytologically Confirmed Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer +2

Start: 2021-06-15End: 2022-02-03Updated: 2022-05-18

Molecular Therapy — Oncolytics2023-12-0127 citations

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Journal for ImmunoTherapy of Cancer2023-05-0122 citations

265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

Regular and Young Investigator Award Abstracts2020-11-011 citations

JAVELIN Solid Tumor Clinical Trials Evaluating Use of Avelumab

Oncology Times2017-05-31

M9241

Sponsors

Conditions

Phase 1

Related Papers